RxDoctor Payments Data

Iva Todorova, APRN

Family · Seminole, FLNPI 1578913968

Payments from drug & device makers

$1,439in general payments, 2019–2025

Across 71 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$176
  • Pfizer$175
  • GSK$167
  • AbbVie$158
  • AstraZeneca$147
  • Lilly USA, LLC$111
  • plus $504 from 12 others

What the payments were for

  • Food & beverage$1,439100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,439 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$4,677
Medicare patients
37
Services billed
83

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$147,402
OzempicSemaglutide136$143,385
XeljanzTofacitinib Citrate12$68,293
FarxigaDapagliflozin Propanediol59$57,105
JardianceEmpagliflozin34$46,971
JanuviaSitagliptin Phosphate42$42,218
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$41,328
XareltoRivaroxaban28$39,392
ProliaDenosumab16$28,129
MounjaroTirzepatide22$21,316
JanumetSitagliptin Phos/Metformin Hcl13$20,041
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$17,800
Levothyroxine Sodium1,002$14,171
Spiriva RespimatTiotropium Bromide12$13,433
Celecoxib140$12,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Xeljanz$175$215,695167 claims
Novo NordiskOzempic$19$143,385136 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$147$81,86592 claims
MerckJanuvia, Janumet, Janumet Xr$20$68,29166 claims
GSKTrelegy Ellipta, Breo Ellipta$167$46,48354 claims
Johnson & JohnsonXarelto$49$39,39228 claims
AmgenProlia$103$28,12916 claims
Lilly USA, LLCMounjaro$111$21,31622 claims
AbbVieSynthroid$158$3,93868 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 14,618 family providers in Florida.

Other family in Seminole

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →